Cargando…

The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review

BACKGROUND AND OBJECTIVES: Economic evaluations provide information to aid the optimal utilization of limited healthcare resources. Costs of biologics for Rheumatoid arthritis (RA) are remarkably high, which makes these agents an important target for economic evaluations. This systematic review aims...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joensuu, Jaana T., Huoponen, Saara, Aaltonen, Kalle J., Konttinen, Yrjö T., Nordström, Dan, Blom, Marja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363598/ https://www.ncbi.nlm.nih.gov/pubmed/25781999 http://dx.doi.org/10.1371/journal.pone.0119683

Ejemplares similares

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis
por: Huoponen, Saara, et al.
Publicado: (2019)

Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis
por: Aaltonen, Kalle J., et al.
Publicado: (2012)

A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases
por: Huoponen, Saara, et al.
Publicado: (2015)

Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease
por: Huoponen, Saara, et al.
Publicado: (2020)

How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers
por: Chatzidionysiou, Katerina, et al.
Publicado: (2020)

Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland – a matched cohort study
por: Taipale, Heidi, et al.
Publicado: (2022)

Circadian Timekeeping Is Disturbed in Rheumatoid Arthritis at Molecular Level
por: Kouri, Vesa-Petteri, et al.
Publicado: (2013)

Fibroblast biology: Signals targeting the synovial fibroblast in arthritis
por: Konttinen, Yrjö T, et al.
Publicado: (2000)

Differentially Expressed in Chondrocytes 2 (DEC2) Increases the Expression of IL-1β and Is Abundantly Present in Synovial Membrane in Rheumatoid Arthritis
por: Olkkonen, Juri, et al.
Publicado: (2015)

Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment
por: Kowalik, Krzysztof, et al.
Publicado: (2018)

Administration costs of intravenous biologic drugs for rheumatoid arthritis
por: Soini, Erkki J, et al.
Publicado: (2013)

Soluble biglycan: a potential mediator of cartilage degradation in osteoarthritis
por: Barreto, Goncalo, et al.
Publicado: (2015)

Outcome of prosthesis exchange for infected knee arthroplasty: the effect of treatment approach: A systematic review of the literature
por: Jämsen, Esa, et al.
Publicado: (2009)

Biologic monotherapy in the treatment of rheumatoid arthritis
por: Detert, Jacqueline, et al.
Publicado: (2015)

Treatment with Biologicals in Rheumatoid Arthritis: An Overview
por: Rein, Philipp, et al.
Publicado: (2017)

Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review
por: Lau, Chak Sing, et al.
Publicado: (2017)

Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA
por: Chastek, Benjamin, et al.
Publicado: (2017)

Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment—A Systematic Literature Review
por: Batko, Bogdan, et al.
Publicado: (2019)

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
por: Boyadzieva, Vladimira V., et al.
Publicado: (2018)

Rheumatoid arthritis is associated with increased DKK1 expression and disturbances in the bone turnover regulating genes
por: Caetano-Lopes, Joana, et al.
Publicado: (2011)

Immune-Regulatory Mechanisms in Systemic Autoimmune and Rheumatic Diseases
por: Takakubo, Yuya, et al.
Publicado: (2012)

Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
por: Emery, Paul, et al.
Publicado: (2018)

Indirect costs of rheumatoid arthritis
por: Raciborski, Filip, et al.
Publicado: (2015)

Cost-Effectiveness Modelling of Sequential Biologic Strategies for the Treatment of Moderate to Severe Rheumatoid Arthritis in Finland
por: Puolakka, K, et al.
Publicado: (2012)

Healthcare costs and productivity losses in treatment-resistant depression in Finland
por: Rannanpää, S., et al.
Publicado: (2022)

Investigating the Value of Abatacept in the Treatment of Rheumatoid Arthritis: A Systematic Review of Cost-Effectiveness Studies
por: Athanasakis, Kostas, et al.
Publicado: (2013)

REGENERATIVE MEDICINE – INITIATIVE À LA CARTE A remedy to the blood thirsty count Dracula?
por: Konttinen, Yrjö T, et al.
Publicado: (2008)

Modelling Cost-Effectiveness of Biologic Treatments Based on Disease Activity Scores for the Management of Rheumatoid Arthritis in Spain
por: Beresniak, Ariel, et al.
Publicado: (2011)

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy
por: Degli Esposti, Luca, et al.
Publicado: (2016)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan
por: Mahlich, Jörg, et al.
Publicado: (2016)

Automated dose dispensing service for primary healthcare patients: a systematic review
por: Sinnemäki, Juha, et al.
Publicado: (2013)

Biological Response Modifiers in Rheumatoid Arthritis: Systematic Review and Meta-analysis of Safety
por: Tank, Nitishkumar D., et al.
Publicado: (2017)

A Systematic Review to Identify the Effects of Biologics in the Feet of Patients with Rheumatoid Arthritis
por: Ramos-Petersen, Laura, et al.
Publicado: (2020)

Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis
por: Patel, Dipen, et al.
Publicado: (2019)

Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate
por: Tkacz, Joseph, et al.
Publicado: (2020)

Biologicals in rheumatoid arthritis: current and future
por: Avci, Ali Berkant, et al.
Publicado: (2015)

Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis
por: Lindström, Ulf, et al.
Publicado: (2019)

Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy
por: Barton, Jennifer L
Publicado: (2009)

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
por: Manova, Manoela, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8rr3re5u9o1iecqcrj6o94qtk0